A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors
Authors
Keywords
Tivantinib, ARQ-197, Topotecan, MET phosphorylation, Circulating tumor cells
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 82, Issue 4, Pages 723-732
Publisher
Springer Nature America, Inc
Online
2018-08-20
DOI
10.1007/s00280-018-3672-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
- (2017) Ravi Salgia MOLECULAR CANCER THERAPEUTICS
- A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-typeKRASwho have received first-line systemic therapy
- (2016) Cathy Eng et al. INTERNATIONAL JOURNAL OF CANCER
- A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
- (2016) Christos E. Kyriakopoulos et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
- (2015) Takuji Okusaka et al. CANCER SCIENCE
- Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
- (2015) Sara M. Tolaney et al. INVESTIGATIONAL NEW DRUGS
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
- (2014) S. Pant et al. ANNALS OF ONCOLOGY
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
- (2014) Igor Puzanov et al. INVESTIGATIONAL NEW DRUGS
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
- (2014) Antonio Calles et al. Molecular Oncology
- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
- (2013) A Santoro et al. BRITISH JOURNAL OF CANCER
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
- (2013) Yoon-Koo Kang et al. INVESTIGATIONAL NEW DRUGS
- A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
- (2013) Darren R. Feldman et al. INVESTIGATIONAL NEW DRUGS
- Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer
- (2013) C. E. Rolle et al. MOLECULAR CANCER THERAPEUTICS
- A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
- (2011) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started